NASA
No title available
No title available
hello vonnie
Jules of Nature
Cosimo Galluzzi
Misplaced Lens Cap
dirt enthusiast
Stranger Things
noise dept.
wallacepolsom
izzy's playlists!
No title available
h
ojovivo
trying on a metaphor
oozey mess
Three Goblin Art
we're not kids anymore.
Today's Document
seen from Canada
seen from United States
seen from United Kingdom
seen from United States
seen from Germany
seen from United States
seen from Germany
seen from Portugal
seen from United States
seen from Türkiye
seen from Mauritius
seen from United States
seen from Malaysia
seen from United Kingdom
seen from United States
seen from Canada
seen from United States
seen from United States
seen from United States
seen from Canada
@cdifffoundation
The New Website Is LIVE https://cdiff.foundation
To celebrate the C Diff Foundation’s 10th anniversary cdiff.foundation has been built and officially launched with healthcare providers, patients, family members, and caregivers in mind. Our new website has more than a brand new look. There is an updated NEWS blog where you have the opportunity to sign to receive weekly updates, tips, and information taking place in the C. diff.…
View On WordPress
Ferring’s Microbiome Health Index™ Is a Promising Tool That Measures Disrupted Gut Microbiota after Antibiotic Treatment
Ferring’s Microbiome Health Index™ Is a Promising Tool That Measures Disrupted Gut Microbiota after Antibiotic Treatment
The Microbiome Health Index for post-Antibiotic dysbiosis (MHI-A), is intended to understand and manage the risks of administering antibiotics. Additionally, Ferring hopes the MHI-A will assist in the development of live biotherapeutic products. Ferring Pharmaceuticals announced today that they are developing a prototype biomarker that distinguishes post-antibiotic dysbiosis from healthy gut…
View On WordPress
Vedanta Biosciences Phase 2 Clinical Trial Of VE303 Met Primary Endpoint Through Week 8 Compared With Placebo Of Preventing Recurrent C. difficile Infection (rCDI)
Vedanta Biosciences Phase 2 Clinical Trial Of VE303 Met Primary Endpoint Through Week 8 Compared With Placebo Of Preventing Recurrent C. difficile Infection (rCDI)
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the prevention of recurrent C. difficile infection (CDI) in high-risk patients, met its primary endpoint of…
View On WordPress
Summit Therapeutics IDWeek 2021 E-Poster Provides Enhanced Details About the Newly Discovered Novel Mechanism of Action of Ridinilazole
Summit Therapeutics IDWeek 2021 E-Poster Provides Enhanced Details About the Newly Discovered Novel Mechanism of Action of Ridinilazole
Summit Therapeutics Inc.is today displaying an important e-Poster at IDWeek 2021. IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). Summit’s e-Poster provides…
View On WordPress
Acurx Pharmaceuticals Presents Abstract and Poster Presentation at IDWeek: New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for C. difficile Infections
Acurx Pharmaceuticals Presents Abstract and Poster Presentation at IDWeek: New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for C. difficile Infections
Acurx Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021: Title: An Open-label Phase 2a study…
View On WordPress
Seres Therapeutics Announced Data From Its Phase 3 ECOSPOR III Study Evaluating SER-109, An Investigational Oral Microbiome Therapy For Recurrent C. diff. (C. difficile) Infection
Seres Therapeutics Announced Data From Its Phase 3 ECOSPOR III Study Evaluating SER-109, An Investigational Oral Microbiome Therapy For Recurrent C. diff. (C. difficile) Infection
Seres Therapeutics, Inc. a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI), will be presented at the IDWeek 2021 Virtual Conference (Sept. 29-Oct. 3). The Company will be presenting seven posters and oral presentations related to SER-109 and…
View On WordPress
Gut Microbiome and Dietary Fiber Diet Influences Microbial Metabolism
Gut Microbiome and Dietary Fiber Diet Influences Microbial Metabolism
In normal conditions, meal ingestion induces satiation and fullness which, depending on the type of foods ingested, individual sensitivity and reflex activity, may have a pleasurable dimension leading to digestive well-being. However, 84% of people with IBS experience digestive symptoms related to food intake, including abdominal pain, bloating and abdominal distension, which are not secondary to…
View On WordPress
Genomic Characterization of Nine Clostridioides difficile Strains Isolated from Korean Patients Diagnosed With a CDI
Genomic Characterization of Nine Clostridioides difficile Strains Isolated from Korean Patients Diagnosed With a CDI
Seung Woo Ahn # 1, Se Hee Lee # 1, Uh Jin Kim 2, Hee-Chang Jang 2, Hak-Jong Choi 1, Hyon E Choy 3, Seung Ji Kang 4, Seong Woon Roh 5 Abstract Background: Clostridioides difficile infection (CDI) is an infectious nosocomial disease caused by Clostridioides difficile, an opportunistic pathogen that occurs in the intestine after extensive antibiotic regimens. Results: Nine C. difficile strains…
View On WordPress
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, Announced Final Results of An Analysis From Five Prospective Trials Of Its Investigational Microbiota-Based Live Biotherapeutic RBX2660
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, Announced Final Results of An Analysis From Five Prospective Trials Of Its Investigational Microbiota-Based Live Biotherapeutic RBX2660
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The abstract, presented at IDWeek 2021, represents the first time these data are showcased together, and is one of only four abstracts…
View On WordPress
Risk Factors Following Successful FMT To Resolve a CDI; GI Symptoms
Risk Factors Following Successful FMT To Resolve a CDI; GI Symptoms
Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT) Jessica R Allegretti 1 2, Zain Kassam 3 4 5, Monika Fischer 6, Colleen Kelly 7, Walter W Chan 1 2 Affiliations expand Abstract Background: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection…
View On WordPress
Researchers Find Ultrasensitive Stool Toxin Detection and Concentration Correlated with Severe Baseline In Hospitalized Patients With C. difficile Infection
Researchers Find Ultrasensitive Stool Toxin Detection and Concentration Correlated with Severe Baseline In Hospitalized Patients With C. difficile Infection
Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with Clostridioides difficile infection Carolyn D Alonso, Ciarán P Kelly, Kevin W Garey, Anne J Gonzales-Luna, David Williams, Kaitlyn Daugherty, Christine Cuddemi, Javier Villafuerte-Gálvez, Nicole C White, Xinhua Chen, Hua Xu, Rebecca Sprague, Caitlin…
View On WordPress
Home Care ♥ Items That Should Not Be Kept In the Bathroom
Home Care ♥ Items That Should Not Be Kept In the Bathroom
Did You Know………….. Bathrooms are the perfect breeding ground for mold and mildew, and your towels are easily susceptible to these gross fungi. It’s fine to keep one towel hung up in the bathroom, as long as you swap it out once a week. Turning on an exhaust fan can help dry out the room and your damp towel faster. It is best to store extra towels in a well ventilated closet. And because there…
View On WordPress
JAMA: Prevalence of Detection of CDI (C. difficile) Among Asymptomatic Children, A Systematic Review and Meta-analysis
JAMA: Prevalence of Detection of CDI (C. difficile) Among Asymptomatic Children, A Systematic Review and Meta-analysis
Sarah R. Tougas, BScN, MD1; Nidhi Lodha, MBBS, MSc1; Ben Vandermeer, PhD2; et alDiane L. Lorenzetti, PhD3; Phillip I. Tarr, MD4,5; Gillian A. M. Tarr, PhD6; Linda Chui, PhD7; Otto G. Vanderkooi, MD8,9; Stephen B. Freedman, MDCM, MSc10,11 JAMA Pediatr. Published online August 2, 2021. doi:10.1001/jamapediatrics.2021.2328 Question What is the prevalence of Clostridioides…
View On WordPress
Contagion Live Presents: Where Are We With Clostridioides Difficile?
Contagion Live Presents: Where Are We With Clostridioides Difficile?
MEDIA PARTNER In this episode, our 1 Big Question is: Looking at C diff as a whole, would you say the medical community is doing a better job overall of treatment and what challenges remain? We interviewed Sahil Khanna, MBBS, MS, who is professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic; Glenn Tillotson, PhD, FIDSA, FCCP, GST Micro LLC; Payal K. Patel, MD,…
View On WordPress
Antimicrobials Working Group (AWG) Announced the Addition of ACURX Pharmaceuticals To Its Coalition Of Companies With the Mission To Combat Drug Resistant Infections
Antimicrobials Working Group (AWG) Announced the Addition of ACURX Pharmaceuticals To Its Coalition Of Companies With the Mission To Combat Drug Resistant Infections
The Antimicrobials Working Group (AWG) announced August 5, 2021 the addition of Acurx Pharmaceuticals, Inc. to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 13 antimicrobial drug companies. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for…
View On WordPress
American Society of Colon and Rectal Surgeons (ASCRS) June 2021 Clinical Practice Guidelines: Management of a CDI
American Society of Colon and Rectal Surgeons (ASCRS) June 2021 Clinical Practice Guidelines: Management of a CDI
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection Poylin, Vitaliy M.D.1; Hawkins, Alexander T. M.D., M.P.H.2; Bhama, Anuradha R. M.D.3; Boutros, Marylise M.D.4; Lightner, Amy L. M.D.5; Khanna, Sahil M.B.B.S., M.S.6; Paquette, Ian M. M.D.7; Feingold, Daniel L. M.D.8; Prepared by the Clinical Practice Guidelines…
View On WordPress
A Global Stroll In the Park To Raise C. diff. Awareness On September 25th
A Global Stroll In the Park To Raise C. diff. Awareness On September 25th
Join Us For a Stroll In the Park on September 25th In-Person, and On-Line To Raise C. diff. Awareness Around the Globe! September 25th is right around the corner and we are so excited to have this opportunity to walk together either in-person at the following park locations: Sims Park, New Port Richey, FL Milton A. Votee Park, Teaneck, NJ Brown Street Park Complex, Spring City,…
View On WordPress